AFP and hepatocellular carcinoma: Therapeutically, these DEX successfully induced AFP‐specific CTL responses, significantly increasing anti‐tumor immune activity against HCC by enhancing T cell proliferation and IFN‐γ secretion, showing potential for targeted cancer immunotherapy​.